Company Description
Arrayit Corporation leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Headquartered in Sunnyvale, California, the company provides products and services to scientists and clinicians to explore the human genome, as well as the genomes of plants and animals. Nearly every major research center in the world uses Arrayit products including research laboratories, pharmaceutical companies, universities, biotechnology companies, hospitals, government agencies, and nonprofit research organizations. The Company's product portfolio includes microarrayers, microarray scanners, microarray printing, substrates and slides, amplification and labeling, purification kits, microarray hardware, buffers and solutions, microarray cleanrooms, books and software, comparative genomic hybridization microarrays and microarray platforms.
Financials, Fundamental Metrics & Ratios
| Revenue (Most Recent Fiscal Year) |
-- |
| Net Income (Most Recent Fiscal Year) |
-- |
| PE Ratio (Current Year Earnings Estimate) |
-- |
| PE Ratio (Trailing 12 Months) |
-- |
| PEG Ratio (Long Term Growth Estimate) |
-- |
| Price to Sales Ratio (Trailing 12 Months) |
-- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) |
-- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) |
-- |
| Pre-Tax Margin (Trailing 12 Months) |
-- |
| Net Margin (Trailing 12 Months) |
-- |
| Return on Equity (Trailing 12 Months) |
-- |
| Return on Assets (Trailing 12 Months) |
-- |
| Current Ratio (Most Recent Fiscal Quarter) |
-- |
| Quick Ratio (Most Recent Fiscal Quarter) |
-- |
| Debt to Common Equity (Most Recent Fiscal Quarter) |
-- |
| Inventory Turnover (Trailing 12 Months) |
-- |
| Book Value per Share (Most Recent Fiscal Quarter) |
-- |
| Earnings per Share (Most Recent Fiscal Quarter) |
-- |
| Earnings per Share (Most Recent Fiscal Year) |
-- |
| Diluted Earnings per Share (Trailing 12 Months) |
-- |